← All indications
Axial Spondyloarthritis
A spectrum of chronic inflammatory conditions affecting the axial joints (e.g., SPINE), characterized by pain, stiffness of joints (ANKYLOSIS), reduced mobility and inflammation. When joint inflammation and damage are visible on regular X-rays it is called ANKYLOSING SPONDYLITIS; otherwise it is referred to as NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. HLA-B27 ANTIGEN is a biomarker and IL-23/IL-17 pathway a potential therapeutic target for axial and other related spondyloarthritis.
Subtype terms (2)
More specific conditions that are subtypes of Axial Spondyloarthritis in the MeSH hierarchy.
- Non-Radiographic Axial Spondyloarthritis
5 drugs (3 approved, 2 experimental)
- Spondylitis, Ankylosing
94 drugs (57 approved, 37 experimental)
Drugs by status
Phase 4 trials (20)
- diclofenac
- 23-valent pneumococcal polysaccharide vaccine
- secukinumab
- certolizumab pegol
- golimumab
- tofacitinib
- etanercept
- hydroxychloroquine
- meloxicam
- adalimumab
- pneumococcal 13-valent conjugate vaccine
- indomethacin
- celecoxib
- sulfasalazine
- inactivated influenza vaccine
- infliximab
- upadacitinib
- methotrexate
- varicella zoster virus glycoprotein e antigen
- etoricoxib
Phase 3 trials (9)
Phase 2 trials (9)
Phase 1 trials (3)